Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes

JERUSALEM, October 31, 2014 /True Blue Tribune/ –

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company’s proprietary oral insulin capsules, to treat type 1 diabetes on Monday, November 3, 2014 at 10:00 a.m. Eastern time.

Shareholders and other interested parties may participate in the call by dialing 1-800-323-0845 (domestic) or 1-706-643-1203 (international) and referencing conference ID number 28757299. Slides containing data from the Phase IIa clinical trial will be posted at 7:15 a.m. Eastern time on November 3, 2014 to the company’s website at http://www.oramed.com.

A replay of the conference call will be accessible two hours after its completion through November 9, 2014, by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and referencing conference ID number 28757299.

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801 ). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit   http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected timing thereof, and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact
Oramed Pharmaceuticals
Ariella Nachman
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com 

Carolina Orthopaedic & Sports Medicine Center holds ribbon cutting for new facility

GASTONIA, N.C., Oct. 31, 2014 /True Blue Tribune/ — Carolina Orthopaedic & Sports Medicine Center hosted a ribbon cutting and open house for its new facility, which is located at 2345 Court Drive in Gastonia, on Oct. 2, 2014. The…

Blair Orthopedics surgeon receives national recognition

ALTOONA, Pa., Oct. 31, 2014 /True Blue Tribune/ — Angela W. Rowe, D.O., orthopedic surgeon at Blair Orthopedics, has received the American Osteopathic Academy of Orthopedics’ Award of Fellow. Photo – http://photos.prnewswire.com/prnh/20141030/155605 “It is an honor to be recognized by…

One Mind to Present at Cavendish Global Health Impact Forum

SEATTLE, Oct. 31, 2014 /True Blue Tribune/ — Cavendish Global announced today the selection of One Mind, the leading patient advocacy organization dedicated to benefiting all affected by brain illness and injury, to present at the Cavendish Global Health Impact…

Mike Holmes Hammers Home the Message on Radon – November is Lung Month: protect your lungs, get your home tested

TORONTO, Oct. 31, 2014 /CNW/ – “Get your home tested for radon . . . it could save your life.” That’s the no-nonsense message from Canada’s most trusted contractor, Mike Holmes, in a new media campaign warning Canadians about the…

Digirad Delivers Letter To PDI, Inc. Responding To PDI’s Summary Rejection Of Digirad’s Offer To Acquire Company

SUWANEE, Ga., Oct. 31, 2014 /True Blue Tribune/ – Digirad Corporation (Nasdaq: DRAD) today announced that it has sent a letter to PDI, Inc. (Nasdaq: PDII), a healthcare commercialization services company, responding to PDI’s summary rejection of Digirad’s proposal to…

Semler Reports Third Quarter 2014 Financial Results

PORTLAND, Ore., Oct. 31, 2014 /True Blue Tribune/ — Semler Scientific, Inc. (Nasdaq: SMLR; “Semler”), an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today reported financial results…

Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax™-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses

BALTIMORE, Md., Oct. 31, 2014 /True Blue Tribune/ — Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense (DoD) through the Medical Countermeasure Systems-Joint…

GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City

ORLANDO, Fla., Oct. 31, 2014 /True Blue Tribune/ — Tavistock Development Co. (TDC), a diversified real estate firm owned by Tavistock Group, celebrated the groundbreaking of the GuideWell Innovation Center at Lake Nona Medical City. The 92,000-square-foot, three-story facility is…

PDI, Inc. Announces Date & Time Change for Third Quarter Financial Results Conference Call

PARSIPPANY, N.J., Oct. 31, 2014 /True Blue Tribune/ — PDI, Inc. (Nasdaq: PDII) today announced that it has adjusted the date and time it will release its third quarter 2014 financial results and operational highlights. The company will now release…